Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Avenue Therapeutics, Inc. (ATXI)
Last avenue therapeutics, inc. earnings: 8/14 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.avenuetx.com/investors/investors-home/default.aspx
Company Research
Source: GlobeNewswire
- Topline data remains on track for second quarter of 2024 - MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that all patients have been enrolled in the Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (“SBMA”), also known as Kennedy's Disease. AJ201 is currently the lead drug candidate in the clinic for SBMA, and topline data are anticipated in the second quarter of 2024. “We are pleased with the speed of enrollment in our Phase 1b/2a study evaluating AJ201 for the treatment of SBMA, reflecting the large unmet need in this debilitating neurodegenerative disease,” said Alexandra MacLean, M.D., Chief Executive Officer of Avenue. “We are intently focused on advancing this much needed drug for patients and their caregiv
Show less
Read more
Impact Snapshot
Event Time:
ATXI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATXI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATXI alerts
High impacting Avenue Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATXI
News
- Avenue Therapeutics Announces Reverse Stock Split [Yahoo! Finance]Yahoo! Finance
- Avenue Therapeutics Announces Reverse Stock SplitGlobeNewswire
- Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024GlobeNewswire
- Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate HighlightsGlobeNewswire
ATXI
Sec Filings
- 4/26/24 - Form 8-K
- 4/17/24 - Form 4
- 4/17/24 - Form SC
- ATXI's page on the SEC website